Related Experiment Video

Updated: Aug 30, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

The proteasome: a novel therapeutic target in haematopoietic malignancy

Laura Magill1, Brian Walker, Alexandra E Irvine

  • 1Department of Haemotology, Queen's University of Belfast, UK.

Hematology (Amsterdam, Netherlands)
|October 8, 2003
PubMed

Insights

Synthetic proteasome inhibitors induce apoptosis in cancer cells, highlighting the proteasome as a therapeutic target. Early clinical trials show promise for these inhibitors in treating multiple myeloma.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • The proteasome is crucial for protein degradation in eukaryotic cells.
  • Synthetic proteasome inhibitors have been developed to study its function.
  • These inhibitors show potential for cancer therapy.

Purpose of the Study:

  • To investigate the role of the proteasome in cellular processes.
  • To evaluate proteasome inhibitors as a potential therapeutic strategy.
  • To assess the efficacy of proteasome inhibitors in preclinical cancer models.

Main Methods:

  • Utilized synthetic inhibitors to modulate proteasome activity.
  • Investigated the effects of proteasome inhibition on cell death pathways.
  • Conducted in vitro studies on malignant cell lines.
  • Analyzed data from ongoing clinical trials.

Main Results:

  • Proteasome inhibition selectively induced apoptosis in malignant cells.
  • This suggests the proteasome is a viable therapeutic target.
  • First-generation inhibitors are demonstrating positive outcomes in clinical trials.

Conclusions:

  • The proteasome is a validated therapeutic target for cancer treatment.
  • Proteasome inhibitors represent a promising class of drugs for malignancies.
  • Ongoing clinical trials for multiple myeloma are encouraging.

Related Concept Videos

The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...